The latest coronavirus developments and scientific research on prevention and treatment.
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research. The study questions the assumption that Paxlovid’s effectiveness in reducing… read more.
U.S. hospital occupancy after the end of the Covid-19 pandemic is significantly higher than it was before the pandemic, setting the stage for a hospital bed shortage as… read more.
U.S. outpatient prescriptions for hydroxychloroquine and ivermectin increased 2- to 10-fold above pre-pandemic rates, respectively, to treat COVID-19, despite strong evidence disproving their effectiveness, new UCLA-led research shows…. read more.
Alcohol-related deaths increased 18% during the pandemic, as did hospitalizations related to alcohol use, according to new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241146. In the early part of the… read more.
Two-thirds of people with post-COVID-19 syndrome have persistent, objective symptoms – including reduced physical exercise capacity and reduced cognitive test performances – for a year or more, with… read more.
Researchers have provided the molecular explanation for why some osteoporosis drugs offer protection against Covid-19. The study, by researchers at the University of York, builds on work conducted… read more.
An up-close look at how patients respond to the drug at different times and doses adds nuance to a recent finding that Paxlovid does not work for long… read more.
A year after becoming available, vaccines to protect against RSV in newborns and older adults are being more widely accepted by the American public, according to a new… read more.
Newly published research suggests an association between COVID-19 infection and accelerated kidney function decline, especially among people who had been hospitalized for the infection. The findings were published… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Kostaive, a vaccine intended for the prevention of… read more.
A recent longitudinal study from the University of Toronto reveals the mental health consequences of the COVID-19 pandemic on older adults living with migraine. Using a sample of… read more.
InflaRx N.V., a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
